Pfizer stock is showing downward bias. Where is PFE stock headed?
What Are the Latest Phase 3 Results for Pfizer?Pfizer also flagged that an exploratory analysis failed to show a clear relationship between integrin beta-6 (IB6) expression levels and treatment response, keeping the "who benefits" question open. Detailed trial findings are expected at a future medical meeting, which can become the next sentiment checkpoint for the program.Critical Price Levels to Watch for PFE StockAt $24.77, the stock is trading below every major moving average tracked here—about 3.8% under the 20-day SMA ($25.74), 5.3% under the 50-day SMA ($26.16), 7% under the 100-day SMA ($26.65), and 4.3% under the 200-day SMA ($25.88). That "below the stack" posture keeps rallies more likely to run into supply until price can reclaim at least the 20-day/200-day zone.MACD is the cleaner momentum read right now: it’s below its signal line with a negative histogram, which typically means upside pressure is fading versus the prior upswing unless buyers can reassert control. Structurally, the longer-term backdrop is mixed—there’s still a golden cross from October 2025 (50-day SMA above the 200-day SMA), but the nearer-term crossover has turned bearish with the 20-day SMA below the 50-day SMA.
